Renovaro BioSciences Inc. (NASDAQ: RENB) Aims to Unlock Potential Treatments and Cures for Serious Infectious Diseases and Cancer

August 25, 2023 08:50:00
  • Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV
  • Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat
  • The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results

As an advanced, pre-clinical biotechnology company specializing in cell, gene, and immunotherapy, Renovaro BioSciences (NASDAQ: RENB), formerly Enochian BioSciences Inc., aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.

Renovaro’s oncology platform is now at the forefront of the company’s development activities – primarily focused on pancreatic cancer. The company also plans to include other solid tumors with short life expectancy in the first human Phase I/IIa studies that are on track for mid-2024. Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat.

The company’s novel technology uses cell and gene therapies to promote a renewed immune response against solid tumors. Dr. Anahid Jewett, a renowned cancer researcher at UCLA, independently conducted Renovaro’s two humanized mouse model tests using the company’s novel dendritic cell-based therapy. These important findings were presented at two scientific conferences and were the foundation supporting a pre-IND submission to the US Food and Drug Administration (“FDA”). Notably, the findings from Dr. Jewett’s study consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro’s current product development pipeline includes the following:

  • RENB-DC11 – an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors
  • RENB-HV12 – an engineered allogeneic T-Cell vaccine and HIV vaccine candidate with IND submission is expected in the second half of 2024
  • RENB-HV21 – another potential therapy for HIV that shows promising preliminary results, Renovaro holds an exclusive license and has completed the Pre-IND submission with potential IND submission and human trials expected in 2024
  • RENB-HV01 – Caring Cross, a non-profit corporation, has entered into a sublicense to share profits if the product is commercialized, which has shown that proprietary CAR-T cells cure HIV in mouse models
  • RENB-HB01 – a therapeutic approach that aims to eliminate HBV rapidly, with a two to three-dose treatment regimen

Renovaro recently announced the execution of a binding, exclusive letter of intent (“LOI”) with GEDi Cube, a cutting-edge health AI company. Renovaro’s officials are confident that joining forces with GEDi Cube will help enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches.

“Our advanced cell, gene, and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms,” said Dr. Mark Dybul, CEO of Renovaro ( “I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.